StockData
EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Galmed Pharmaceuticals Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)

Close on Oct 19, 2026

Market cap
$2.71M
P/E (TTM)
0.1
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2025
Ended Sep 30, 2025
Nov 26, 2025Before market open–$0.33–
Q2 FY2025
Ended Jun 30, 2025
Aug 28, 2025Before market open–$0.63–
Q1 FY2025
Ended Mar 31, 2025
May 22, 2025Before market open–$0.62–
Q1 FY2023
Ended Mar 31, 2023
Jun 1, 2023Before market open–$1.09–
Q2 FY2022
Ended Jun 30, 2022
Aug 4, 2022Before market open–––
Q1 FY2022
Ended Mar 31, 2022
May 2, 2022Before market open–––

Press releases

Announcements Galmed Pharmaceuticals filed with the SEC